Drugs / Ecraprost
Ecraprost
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00059657 | Aug 2001 → Nov 2005 | peripheral vascular disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00059644 | Jul 2001 → Jun 2004 | peripheral vascular disease | Tanabe Pharma Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ecraprost | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00059644 ↗ |
| Known as | AS-013 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104574 ↗ |
| Known as | Circulase | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104574 ↗ |
| Modality | Small molecule | — CHEMBL2104574 ↗ |